Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou've had your second Mounjaro injection, you stepped on the scales, and the number hasn't moved. At 2.5mg (the starter dose) visible weight loss in the first two weeks is uncommon, and that's by design rather than a sign anything has gone wrong. The NHS's tirzepatide guidance is clear that this dose is a tolerability step, not the therapeutic level where most people see meaningful change. Read on for what the evidence actually says about the early weeks.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've done everything right. You took your pen on schedule, you've been watching what you eat, and you've checked your weight twice already this week. Nothing. It's genuinely frustrating, and the silence from the scales can feel like evidence that Mounjaro isn't working for you personally.
It almost certainly isn't that. The 2.5mg dose (the one everybody begins on) exists so your digestive system has time to settle before the dose climbs. Tirzepatide slows gastric emptying and adjusts appetite signalling via both GIP and GLP-1 pathways, but those effects build with dose. At 2.5mg, most of what's happening is your gut learning to tolerate the medicine. The appetite suppression that drives meaningful weight reduction tends to arrive more clearly once you reach 5mg, typically after your first four-week pen is complete.
That timeline is built into how Mounjaro weight loss typically unfolds week by week, early weeks are rarely the big-movement weeks. The SURMOUNT-1 trial, which followed participants across 72 weeks, recorded average body-weight reduction of around 20% at the highest dose. The large numbers came from the later months of treatment, not from week two.
So the absence of movement right now is, in most cases, pharmacologically normal. Give the titration schedule the chance to do its job.
Weight isn't a clean signal at the best of times, and it's an especially noisy one in the first fortnight of any new medicine. A few things worth knowing.
Tirzepatide slows gastric emptying noticeably, which can increase the amount of food and fluid sitting in your digestive tract at any given moment. That alone can account for a kilogram or more on the scales without representing stored fat at all. Similarly, any changes to your eating pattern (eating less salt, for instance, or drinking more water) shift how much fluid your body holds day to day.
Muscle tissue is also denser than fat. If you've added any physical activity alongside the medicine, you may be losing fat and gaining or maintaining muscle simultaneously, with the two changes partially cancelling each other on the scales. Waist measurements or how clothes fit are often a more useful early indicator than weight alone.
The practical upshot: weigh yourself at the same time on the same day each week, rather than daily, to reduce the noise. Our guide to what Mounjaro weight loss looks like week to week gives a realistic picture of how the numbers tend to move across the titration schedule, including the weeks where they don't.
For most people, the early weeks of 5mg bring a clearer signal, appetite falls more noticeably, food feels satisfying sooner, and the scales start to respond. Some people see movement sooner; some need the dose to climb to 7.5mg or 10mg before the effect becomes significant. Both are within the normal range of responses. By week eight the majority of people on Mounjaro are seeing measurable change, though the pace varies considerably from person to person.
If you reach week five or six and the scales have moved only minimally or not at all, that is worth raising. Our page on no weight loss at week five covers what questions to ask and what your prescriber will typically consider. A genuine plateau at a therapeutic dose can reflect dietary factors, medication interactions, or a need to review the titration pace, all of which a prescriber can look at.
One practical note on dizziness or other side effects in these early weeks: some people experience lightheadedness as their appetite and fluid intake change. Our guidance on managing dizziness on Mounjaro covers the common reasons and what usually helps.
Mounjaro is a prescription-only medicine; every change to your dose or treatment plan goes through a prescriber, not a self-directed call. If anything about your response in week two feels unexpected (not just the weight, but how you feel physically) that's worth contacting your clinical team about rather than waiting for the next scheduled review. You can reach our team seven days a week.
If you'd like to understand more about how tirzepatide works before your next injection, the full tirzepatide overview covers the mechanism, the evidence and the licensed eligibility criteria in one place. And if you're still deciding whether Mounjaro is the right fit for you, our weight-loss treatment overview sets out the options available through a UK prescriber.
For those thinking about the cost of continuing treatment, our Mounjaro pricing guide explains what legitimate private treatment typically includes. Speak to our prescribers if you want a clinical view on where you are in the process, that conversation is free, and it's where the titration decisions actually get made.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.